Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Social Media Use and Motherhood

NCT07715019 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2026-10-01
Last updated
2026-07-20

Condition(s) studied

Postpartum Period

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

This study aims to analyze the relationship between social media use, body image disorders, sexuality, sleep quality, and physical activity during the postpartum period. For this purpose, we will recruit 85 postpartum women through midwives from the Zamora Health Area. Following the signing of informed consent, participants will complete validated online questionnaires evaluating these dimensions. Participant recruitment and data collection will take place from September to December 2026.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women Within one year postpartum Exclusion Criteria: \-

Primary outcome measure(s)

  • Body Image disorders — Only at Baseline
    Body Shape Questionnaire (BSQ-14) Measurement and Administration: The BSQ-14 is a self-reported, 14-item Likert-scale questionnaire. It measures the multi-dimensional construct of body image, specifically focusing on body shape dissatisfaction, fear of gaining weight, and self-deprecation due to physical appearance over the past four weeks. Scoring: Each item is rated on a 6-point scale ranging from 1 ("Never") to 6 ("Always"). Total scores are calculated by summing all items, yielding a range of 14 to 84, where higher scores reflect greater body shape dissatisfaction and distress. Definitions and Criteria: While the BSQ-14 is primarily used to evaluate the severity of body dissatisfaction along a continuum rather than as a diagnostic tool, established cutoff scores categorize the level of concern. Scores below 38 generally indicate no or mild concern, scores between 39 and 49 represent moderate concern, and scores of 50 or above indicate

Trial sites (1)

FacilityCityRegionStatus
Jose Ignacio Recio Zamora Zamora

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07715019 on ClinicalTrials.gov ↗ ← All trials in Spain